Contact Us

marketing@medicilon.com

ABOUT

Company Profile

Corporate Culture

Management Team

Company History

Message from the CEO

Honors and Awards

SERVICES

SERVICES

01 Drug Discovery

Chemistry Research Biology Research Early Pharmacokinetics

02 Pharmaceutical Research

Intermediates Active Pharmaceutical Ingredients Pharmaceutical preparation Analytical Method Development and Quality Control CMC Filings Analytical Testing Center

03 Preclinical Research

Pharmacology & Pharmacodynamics Drug Safety Evaluation DMPK Bioanalysis IND Filings

PLATFORM

PLATFORM

01 One-stop Integrated Services

Liposome Drug Development Drug Discovery Pharmaceutical Research Preclinical Research Botanical Drug Preclinical R&D

02 Innovative Drug R&D Services

Peptide Drug Conjugate (PDC) Antibody Nucleic Acid Drug Cellular Immunotherapies mRNA Vaccine PROTAC ADC

03 Key Technical Services for Drug R&D

Cytokine and Biomarker Detection Metabolite Identification (MetID) Drug Forming Research Flow Cytometry Technology SEND Format Conversion Flow Sorting NanoString nCounter Detection Routes of Drug Administration

04 Drug Efficacy Evaluation for Common Diseases

Rodent Cerebrovascular Disease Inflammatory and Immune Diseases IO Pharmacodynamic Model

05 High-end Preparations Technology Platform

Skin Topical Preparation Ophthalmic drug Inhalation drug

06 Targeted Drugs R&D Services

STAT3-targeted Drugs R&D Service KRAS-targeted Drugs R&D Service GLP-1 New Drug R&D Service

07 Safety Assessment Lab of Process Chemistry

08 Public Services

CAREERS

Talent Development

Campus Recruitment

Recruitment

NEWS

Medicilon Events

Featured Stories

Market Events

Videos

A.C.E.

INVESTORS

Stock Information

Investment Contact

CLIENT CENTER

Intellectual Property Protection

Clients Testimonials

Downloads

Partnerships

Medicilon Support

Newsletters

CN

中

Medicilon's News and Events

News and Events

Medicilon Events Featured Stories Market Events Videos A.C.E.

News and Events

Hot information：

Top 10 Global CDMO Enterprises| The Meaning of IND, NDA and ANDA| Top 10 Global Clinical Research Organizations in 2021|

Medicilon Events

More

2024-09-13 ·Medicilon Events

Medicilon Non-tumor Pharmacology Service Platform

Medicilon boasts 260+ evaluation models for non-tumor diseases, covering the inflammatory & immune diseases, CNS diseases, digestive diseases, , Metabolic diseases, cardiovascular diseases and other diseases.

More

2024-08-29 ·Medicilon Events

Medicilon Expands Global Presence with Official Opening of Second R&D Center in Massachusetts

In August 2024, Medicilon USA Corp (Medicilon)officially commenced operations at its second R&D center in Massachusetts, USA.

More

2024-07-31 ·Medicilon Events

Medicilon and Hengrui Pharma Deepen Strategic Collaboration to Support Innovation in ADCs, Small Nucleic Acids, and CGT Drugs

On July 17th, Shanghai Medicilon Inc. ("Medicilon") and Jiangsu Hengrui Pharmaceuticals Co., Ltd. ("Hengrui Pharma") reached a strategic collaboration agreement.

More

2024-12-20 ·Medicilon Events

Medicilon Appoints Dr. Lilly Xu as Chief Technology Officer

Medicilon, a leading preclinical contract research organization (CRO), has named Dr. Lilly Xu as its new Chief Technology Officer (CTO). With over 30 years of experience in preclinical drug development, Dr. Xu will lead Medicilon's technological innovation and global expansion, strengthening its capabilities to deliver cutting-edge R&D solutions.

2024-11-19 ·Medicilon Events

Medicilon Boston's Second R&D Center Grandly Sets Sail

On November 15th, Medicilon proudly unveiled its second R&D center in Boston, a milestone that reinforces its commitment to global drug innovation and its strategic expansion into international markets.

2024-10-08 ·Medicilon Events

Entering the ranks of international authoritative testing! Medicilon has been awarded the CNAS accreditation certificate.

Recently, Medicilon successfully passed the rigorous qualification review and assessment by the China National Accreditation Service for Conformity Assessment (CNAS).

2024-09-13 ·Medicilon Events

Preclinical + Clinical Comprehensive Empowerment for Anti-Tumor Drug Development! Medicilon has reached a strategic collaboration with Shanghai GoBroad Cancer Hospital and Start Shanghai Company

Recently, Shanghai Medicilon Inc. (Medicilon) officially signed a tripartite strategic collaboration framework agreement with China Pharmaceutical University Affiliated Shanghai GoBroad Cancer Hospital (Shanghai GoBroad) and Start Shanghai Company (Start Shanghai).

2024-09-13 ·Medicilon Events

Medicilon Non-tumor Pharmacology Service Platform

Medicilon boasts 260+ evaluation models for non-tumor diseases, covering the inflammatory & immune diseases, CNS diseases, digestive diseases, , Metabolic diseases, cardiovascular diseases and other diseases.

2024-08-29 ·Medicilon Events

Medicilon Expands Global Presence with Official Opening of Second R&D Center in Massachusetts

In August 2024, Medicilon USA Corp (Medicilon)officially commenced operations at its second R&D center in Massachusetts, USA.

2024-08-06 ·Medicilon Events

Medicilon's Antibody Technology Targeting Nectin-4 has been Awarded a National Invention Patent

Recently, Medicilon has successfully obtained an invention patent from the National Intellectual Property Administration for its self-developed project titled "Antibodies Targeting Nectin-4 and Their Various Applications"!

2024-07-31 ·Medicilon Events

Medicilon and Hengrui Pharma Deepen Strategic Collaboration to Support Innovation in ADCs, Small Nucleic Acids, and CGT Drugs

On July 17th, Shanghai Medicilon Inc. ("Medicilon") and Jiangsu Hengrui Pharmaceuticals Co., Ltd. ("Hengrui Pharma") reached a strategic collaboration agreement.

2024-07-26 ·Medicilon Events

2024 (The 7th) Toxicity Testing Alternatives and Translational Toxicology International Conference was successfully held in Nanchang

From July 3 to 6, 2024, 2024 (The 7th) Toxicity Testing Alternatives and Translational Toxicology International Conference was successfully held in Nanchang, Jiangxi.

Featured Stories

More

Medicilon's GLP-1 New Drug R&D Service

Medicilon's GLP-1 New Drug R&D Service

Antibody-oligonucleotide conjugates (AOCs) —A new wave of drug conjugates

Antibody-oligonucleotide conjugates (AOCs) —A new wave of drug conjugates

A Nickel-Catalyzed Reductive Alkylation of Aryl Bromides and Chlorides for Sp<sup>3</sup>-Sp<sup>2</sup> Bond Formation

A Nickel-Catalyzed Reductive Alkylation of Aryl Bromides and Chlorides for Sp³-Sp² Bond Formation

More

Market Events

More

A Special Thanksgiving Message From Medicilon

New Approaches to Facilitate Drug Discovery and Development

Join Medicilon at American College of Toxicology (ACT) 2024

Join Medicilon at SITC 2024 in Houston

More

Video

More

PDXO Model: A Significant Advancement in Precision Oncology

Large Animal Models: Essential Tools in Disease Research

The Vital Role of Large Animal Models in Drug Development

Global

Address: 20 Maguire Road, Suite 103, Lexington, MA 02421(America)

Tel: +1(781)535-1428(U.S.)

Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Tel: 0044 7790 816 954 (Europe)

Email: marketing@medicilon.com

Address: 5th Floor, 62, Banpodae-ro 4-gil, Seocho-gu, Seoul, 06719 South Korea

Tel: +82 70-8269-5849

China

Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

Postcode: 201299

Tel: +86 (21) 5859-1500 (main line)

Fax: +86 (21) 5859-6369

© 2023 Shanghai Medicilon Inc. All rights reserved All Rights Reserved Privacy Policy

-->